A slower-than-hoped-for launch of its latest product and a dilutive offering weighed on shares in February.
With reimbursement in place, the test maker can get into the black this year.
With the decline in HPV test sales mostly behind it, the lab-test maker is looking for a stronger 2016 and beyond.
Higher costs of revenue hurt the genomic sequencing company in the fourth quarter.
This genomic sequencing leader appears to be suffering from multiple revenue headwinds -- at least in the near term.
Here's what it will take for this genomic sequencing company to succeed in 2016.
A slower than hoped for launch of the company's new Sequel System is pressuring shares on Monday.
The introduction of a new and cheaper gene sequencing model could give this company an edge.
A double-digit jump on no news.
Investors continue to grow bullish on the company's near term prospects, sending shares to a fresh 52-week high.